Thelansis

  IDH1 mutations represent a subtype of genetic alterations observed in acute myeloid leukemia (AML), constituting approximately 20% of all AML cases. They are linked to poorer survival rates and a reduced likelihood of achieving complete remission. In younger adults with AML, IDH1 mutations occur in 6–10% of cases, while elderly patients exhibit a notably higher frequency of these mutations. Conversely, in pediatric AML cases, IDH mutations are rare, occurring in fewer than 4% of patients. These mutations drive the production of the oncometabolite 2-hydroxyglutarate, facilitating leukemogenesis by impeding normal myeloid differentiation processes. IDH1 inhibitors, oral small-molecule drugs, selectively target mutant IDH proteins to counteract this. Their mechanism involves inhibiting the production of 2-HG and promoting myeloid differentiation. IDH inhibitors can be administered alone or in conjunction with other therapies. Chronic exposure to certain chemicals significantly hei...